左西孟旦治疗急性失代偿性心力衰竭患者的短期疗效和安全性观察  

Short-Term Efficacy and Safety of Levosimendan in the Treatment of Patients with Acute Decompensated Heart Failure

作　　者：胡乐义[1] 周姝[1] 程景林[1] 刘泽岩[1] HU Leyi;ZHOU Shu;CHENG Jinglin(The Second Affiliated Hospital of Anhui Medical University,Anhui Hefei 230601,China)

机构地区：[1]安徽医科大学第二附属医院急诊内科,安徽合肥230601

出　　处：《河北医学》2023年第10期1725-1730,共6页Hebei Medicine

基　　金：安徽医科大学青年科学基金,(编号:2021xkj286)。

摘　　要：目的:分析研究急性失代偿性心力衰竭(ADHF)住院患者使用常规药物联合左西孟旦治疗方案在短期疗程内取得的效果及临床安全性。方法:选取2018年7月至2022年7月安徽医科大学第二附属医院收治的160例ADHF患者为研究对象,根据是否使用左西孟旦分为对照组和实验组,每组各80例,对照组给予常规药物治疗,实验组给予左西孟旦联合常规药物治疗。收集受试者入院时和治疗后1周左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、N末端脑利钠肽前体(N-terminal pro-B-type natriuretic peptide,NTproBNP)、心肌肌钙蛋白I(cardiac troponin I,cTnI)数值及心功能分级,并进行临床疗效评价。结果:经药物治疗后,两组患者LVEF均升高,LVEDD均缩小,NT-proBNP.cTnI水平均下降,数据差异有意义(P<0.05)。两组治疗后对比,实验组LVEF升高、LVEDD缩小、NT-proBNP下降、cTnI下降幅度均优于对照组(P<0.05)。两组临床疗效对比差异无意义(P>0.05)。结论:急性失代偿性心力衰竭住院患者给予左西孟旦联合常规药物治疗能改善心肌功能相关指标,减缓患者临床病症,且安全有效。Objective:To analyze and study the results and clinical safety of a treatment regimen of conventional drugs combined with levosimendan in hospitalized patients with acute decompensated heart failure(ADHF)over a short course of treatment.Methods:A total of 160 patients with ADHF admitted to the Second Affiliated Hospital of Anhui Medical University from July 2018 to July 2022 were selected and divided into control group with conventional medication and experimental group with levosimendan combined with conventional medication,80 cases in each group.Left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),N-terminal pro-B-type natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI),and cardiac functional grading were collected at admission and one week after treatment.At the same time,the therapeutic effect was analyzed and evaluated.Results:After treatment,LVEF levels of all subjects increased(both P<0.05).There were a significant decrease in the level of LVEDD、NT-proBNP、cTnI for both groups compared with those before treatment(both P<0.05).After the treatment of levosimendan,the magnitude of changes in LVEF,LVEDD,NT-proBNP and cTnI of the patients in the experimental group was better than that in the control group,and the difference between the two groups was significant(all P<0.05).Conclusion:Levosimendan in combination with conventional drugs improves myocardial function and slows down clinical symptoms in hospitalized patients with acute decompensated heart failure,and is safe and effective.

关 键 词：急性失代偿性心力衰竭 左西孟旦 左心室射血分数 疗效 

分 类 号：R541.6[医药卫生—心血管疾病]